Announcements Trials
Browse Landscape

Phase

Phase 2 3

Status

Recruiting 15Terminated 6Completed 5Active not recruiting 5Not yet recruiting 4Withdrawn 3Unknown 3No longer available 1

Sponsor Class

OTHER 3NETWORK 1

Study Type

Interventional 3

Sponsor

Cancer Type

Breast 2Genitourinary 1CNS 1

Conditions

Breast Neoplasms 2Prostatic Neoplasms 1Neoplasm Metastasis 1Brain Neoplasms 1

Interventions

Radiotherapy 91pembrolizumab 88Cyclophosphamide 84Gemcitabine 70Cisplatin 70Magnetic Resonance Spectroscopy 65Carboplatin 60Radiosurgery 55Paclitaxel 55Nivolumab 48Dexamethasone 45Bevacizumab 42Biopsy 41Fluorouracil 39durvalumab 37Surveys and Questionnaires 36Docetaxel 36fludarabine 35Doxorubicin 35Radiation 33Oxaliplatin 33Capecitabine 33Rituximab 32fludarabine phosphate 31Leucovorin 31Cytarabine 30Melphalan 29Etoposide 28Pemetrexed 27Irinotecan 27

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Withdrawn × OTHER × neratinib × Clear all
NCT04901299 2023-08-01

HER2-Signal

Massachusetts General Hospital

Phase 2 Withdrawn
Breast

Breast Neoplasms, Neoplasm Metastasis

NCT04781374 2023-07-11

Neratinib in Patients With Metastatic Castration-Resistant Prostate Cancer

Beth Israel Deaconess Medical Center

Phase 2 Withdrawn
Genitourinary

Prostatic Neoplasms

NCT04856475 2022-03-02

NeraBrain

Jules Bordet Institute

Phase 2 Withdrawn
BreastCNS

Brain Neoplasms, Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡